Eli Lilly shifts 80% of endotoxin testing to recombinant factor C

Horseshoe crab harvest for Limulus amebocyte lysate production reached approximately 200,000 animals annually in Massachusetts by 2024, with nationwide biomedical removals tripling over two decades per Atlantic States Marine Fisheries Commission records. The 15 percent post-bleeding mortality rate documented in commission estimates compounds direct fishing pressure and produces measurable declines in egg availability for migratory shorebirds. Massachusetts responded with a 2023 harvest cap and a 2024 April-June spawning closure covering 90 percent of the season.

Recombinant factor C replicates the LPS-binding protein without animal sourcing. Lilly’s internal validation across thousands of samples on hundreds of products showed equivalent or superior performance to natural lysate, aligning with peer-reviewed comparisons in PDA Journal of Pharmaceutical Science and Technology. The shift severs the direct mortality link while maintaining pharmacopeial compliance for vaccines, biologics, and devices.

Ecosystem modeling indicates that sustained harvest reductions above 30 percent could stabilize crab spawning biomass within five years and restore Red Knot stopover forage. Remaining barriers include slower USP chapter adoption for rFC and variable state permitting outside Massachusetts. Full industry transition hinges on FDA and EMA formal recognition of the synthetic reagent as a standalone compendial method.

Operational outcome is a measurable drop in annual biomedical mortality once remaining Lilly sites and peer manufacturers complete validation, directly lowering pressure on the Delaware Bay and Cape Cod populations.